Trulieve Cannabis (NYSE:TRLV – Get Free Report) and Journey Medical (NASDAQ:DERM – Get Free Report) are both consumer staples companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.
Valuation & Earnings
This table compares Trulieve Cannabis and Journey Medical”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Trulieve Cannabis | $1.08 billion | 1.93 | -$116.38 million | $0.20 | 54.18 |
| Journey Medical | $68.18 million | 1.79 | -$11.43 million | ($0.18) | -24.06 |
Journey Medical has lower revenue, but higher earnings than Trulieve Cannabis. Journey Medical is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
7.2% of Journey Medical shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by insiders. Comparatively, 14.5% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current recommendations for Trulieve Cannabis and Journey Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Trulieve Cannabis | 1 | 1 | 1 | 0 | 2.00 |
| Journey Medical | 2 | 0 | 2 | 0 | 2.00 |
Trulieve Cannabis currently has a consensus target price of $15.00, suggesting a potential upside of 38.44%. Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 200.23%. Given Journey Medical’s higher possible upside, analysts plainly believe Journey Medical is more favorable than Trulieve Cannabis.
Profitability
This table compares Trulieve Cannabis and Journey Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Trulieve Cannabis | -41.22% | -0.34% | -0.14% |
| Journey Medical | -7.34% | -16.15% | -5.38% |
About Trulieve Cannabis
Trulieve Cannabis Corp. is a U.S. cannabis company that cultivates, processes and sells cannabis products through a vertically integrated business. Its offerings include flower, concentrates, vape products, edibles and other cannabis products, sold under brands such as Trulieve and Modern Flower. Founded in Florida in 2015, the company built its business in that state and expanded into other U.S. markets, including Arizona and Pennsylvania. Its operations and product offerings are shaped by the regulations in each state where it operates.
About Journey Medical
Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
